Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency

Summary

Antithrombin is the main endogenous anticoagulant. Impaired function or deficiency of this molecule significantly increases the risk of thrombosis. We studied the genetic variability of SERPINC1, the gene encoding antithrombin, to identify mutations affecting regulatory regions with functional effect on its levels. We sequenced 15,375 bp of this gene, including the potential promoter region, in three groups of subjects: five healthy subjects with antithrombin levels in the lowest (75%) and highest (115%) ranges of our population, 14 patients with venous thrombosis and a moderate antithrombin deficiency as the single thrombophilic defect, and two families with type I antithrombin deficiency who had neither mutations affecting exons or flanking regions, nor gross gene deletions. Our study confirmed the low genetic variability of SERPINC1, particularly in the coding region, and its minor influence in the heterogeneity of antithrombin levels. Interestingly, in one family, we identified a g.2143 C>G transversion, located 170 bp upstream from the translation initiation codon. This mutation affected one of the four regions located in the minimal promoter that have potential regulatory activity according to previous DNase footprinting protection assays. Genotype-phenotype analysis in the affected family and reporter analysis in different hepatic cell lines demonstrated that this mutation significantly impaired, although it did not abolish, the downstream transcription. Therefore, this is the first mutation affecting a regulatory region of the SERPINC1 gene associated with antithrombin deficiency. Our results strongly sustain the inclusion of the promoter region of SERPINC1 in the molecular analysis of patients with antithrombin deficiency.

Keywords

SERPINC1 - antithrombin - promoter - polymorphisms - thrombosis

• References

• 1 Abildgaard U. Antithrombin--early prophecies and present challenges. Thromb Haemost 2007; 98: 97-104.
• 2 Rau JC, Beaulieu LM, Huntington JA. et al. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007; 05 (Suppl. 01) 102-115.
• 3 Bayston TA, Lane DA. Antithrombin: molecular basis of deficiency. Thromb Haemost 1997; 78: 339-343.
• 4 Garcia de Frutos P. Mechanisms of thrombophilia. Thromb Haemost 2007; 98: 485-487.
• 5 Lane DA, Bayston T, Olds RJ. et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77: 197-211.
• 6 Olds RJ, Lane DA, Chowdhury V. et al. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry 1993; 32: 4216-4224.
• 7 Hernandez-Espinosa D, Ordonez A, Vicente V. et al. Factors with conformational effects on haemostatic serpins: implications in thrombosis. Thromb Haemost 2007; 98: 557-563.
• 8 Bock SC, Levitan DJ. Characterization of an unusual DNA length polymorphism 5’ to the human antithrombin III gene. Nucleic Acids Res 1983; 11: 8569-8582.
• 9 Prochownik EV. Relationship between an enhancer element in the human antithrombin III gene and an immunoglobulin light-chain gene enhancer. Nature 1985; 316: 845-848.
• 10 Fernandez-Rachubinski FA, Weiner JH, Blajchman MA. Regions flanking exon 1 regulate constitutive expression of the human antithrombin gene. J Biol Chem 1996; 271: 29502-29512.
• 11 Ochoa A, Brunel F, Mendelzon D. et al. Different liver nuclear proteins binds to similar DNA sequences in the 5’ flanking regions of three hepatic genes. Nucleic Acids Res 1989; 17: 119-133.
• 12 Sheffield WP, Wu YI, Blajchman MA. Antithrombin: Structure and Function. In: Molecular Basis of Thrombosis and Hemostasis. New York: Marcel Dekker, Inc; 1995: 355-377.
• 13 Corral J, Huntington JA, Gonzalez-Conejero R. et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost 2004; 02: 931-939.
• 14 Corral J, Aznar J, Gonzalez-Conejero R. et al. Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation 2004; 110: 1303-1307.
• 15 Sole X, Guino E, Valls J. et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928-1929.
• 16 Anton AI, Teruel R, Corral J. et al. Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica 2009; 94: 589-592.
• 17 Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007; 67: 1429-1440.
• 18 Luxembourg B, Delev D, Geisen C. et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
• 19 Bezemer ID, Bare LA, Doggen CJ. et al. Gene variants associated with deep vein thrombosis. J Am Med Assoc 2008; 299: 1306-1314.
• 20 Austin H, De SC, Lally C. et al. New gene variants associated with venous thrombosis: a replication study in White and Black Americans. J Thromb Haemost 2011; 09: 489-495.
• 21 Tait RC, Walker ID, Islam SI. et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-480.
• 22 Conlan MG, Folsom AR, Finch A. et al. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Thromb Haemost 1994; 72: 551-556.
• 23 Souto JC, Almasy L, Borrell M. et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 1546-1551.
• 24 Corral J, Vicente V, Carrell RW. Thrombosis as a conformational disease. Haema-tologica 2005; 90: 238-246.
• 25 Westrick RJ, Ginsburg D. Modifier genes for disorders of thrombosis and hemostasis. J Thromb Haemost 2009; 07 (Suppl. 01) 132-135.
• 26 Tremp GL, Duchange N, Branellec D. et al. A 700-bp fragment of the human antithrombin III promoter is sufficient to confer high, tissue-specific expression on human apolipoprotein A-II in transgenic mice. Gene 1995; 156: 199-205.